
Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …
A new treatment for chronic migraine prevention, co-developed by Novartis (NYSE: NVS) and Amgen (NASDAQ: AMGN), showed a statistically significant …

